These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
335 related items for PubMed ID: 16210036
1. Essential thrombocythemia. Finazzi G, Harrison C. Semin Hematol; 2005 Oct; 42(4):230-8. PubMed ID: 16210036 [Abstract] [Full Text] [Related]
2. Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk. Barbui T, Finazzi G. Semin Thromb Hemost; 2007 Jun; 33(4):321-9. PubMed ID: 17525889 [Abstract] [Full Text] [Related]
3. Expertise-based management in essential thrombocythemia and polycythemia vera. Finazzi G, Barbui T. Cancer J; 2007 Jun; 13(6):372-6. PubMed ID: 18032974 [Abstract] [Full Text] [Related]
4. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Nand S, Stock W, Godwin J, Fisher SG. Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610 [Abstract] [Full Text] [Related]
5. Risk-adapted therapy in essential thrombocythemia and polycythemia vera. Finazzi G, Barbui T. Blood Rev; 2005 Sep; 19(5):243-52. PubMed ID: 15963833 [Abstract] [Full Text] [Related]
6. Clinical parameters for determining when and when not to treat essential thrombocythemia. Barbui T, Finazzi G. Semin Hematol; 1999 Jan; 36(1 Suppl 2):14-8. PubMed ID: 9930552 [Abstract] [Full Text] [Related]
7. [A management program for primary thrombocytopenia]. Knutsen H, Bruserud O. Tidsskr Nor Laegeforen; 1999 Sep 30; 119(23):3431-4. PubMed ID: 10553341 [Abstract] [Full Text] [Related]
8. Current opinion in essential thrombocythemia: pathogenesis, diagnosis, and management. Tefferi A, Murphy S. Blood Rev; 2001 Sep 30; 15(3):121-31. PubMed ID: 11735160 [Abstract] [Full Text] [Related]
9. Acquired thrombophilia in pregnancy: essential thrombocythemia. Griesshammer M, Grünewald M, Michiels JJ. Semin Thromb Hemost; 2003 Apr 30; 29(2):205-12. PubMed ID: 12709924 [Abstract] [Full Text] [Related]
10. Management of Philadelphia negative chronic myeloproliferative disorders in pregnancy. Griesshammer M, Struve S, Barbui T. Blood Rev; 2008 Sep 30; 22(5):235-45. PubMed ID: 18617299 [Abstract] [Full Text] [Related]
11. Treatment indications and choice of a platelet-lowering agent in essential thrombocythemia. Barbui T, Finazzi G. Curr Hematol Rep; 2003 May 30; 2(3):248-56. PubMed ID: 12901347 [Abstract] [Full Text] [Related]
12. Diagnosis of essential thrombocythemia at platelet counts between 400 and 600x10(9)/L. Gruppo Italiano Malattie Mieloproliferative Croniche(GIMMC). Sacchi S, Vinci G, Gugliotta L, Rupoli S, Gargantini L, Martinelli V, Baravelli S, Lazzarino M, Finazzi G. Haematologica; 2000 May 30; 85(5):492-5. PubMed ID: 10800165 [Abstract] [Full Text] [Related]
13. How to manage essential thrombocythemia. Finazzi G. Leukemia; 2012 May 30; 26(5):875-82. PubMed ID: 22051530 [Abstract] [Full Text] [Related]
15. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications. Michiels JJ, Berneman Z, Van Bockstaele D, van der Planken M, De Raeve H, Schroyens W. Semin Thromb Hemost; 2006 Apr 30; 32(3):174-207. PubMed ID: 16673274 [Abstract] [Full Text] [Related]